Loading...
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of PARP inhibitors is based on the DNA repair vulnerability of many ovarian cancer cells, and multiple mechanisms of action o...
Saved in:
| Published in: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5405993/ https://ncbi.nlm.nih.gov/pubmed/28491146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016687254 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|